

CHIR0035-100 (PP023796.0001)
SERIAL NO.: 10/052,482

PATENT
FILED: November 8, 2001

AMENDMENTS TO THE CLAIMS:

Please cancel claims 1-14 and 17-19 without prejudice.

Please amend claims 15 and 16 as follows:

Please add new claims 20-22.

This listing of claims will replace all prior versions, and listings, of claims in the application:

Claims 1-14 (Canceled)

15. **(Currently Amended)** ~~A polypeptide~~ An isolated antibody which specifically binds to a protein encoded by a nucleic acid comprising a nucleic acid selected from the group consisting of the sequences outlined in Tables 1-40 SEQ ID NO:160, 161 or 162.

16. **(Currently Amended)** ~~A polypeptide~~ The isolated antibody according to claim 15 ~~comprising an antibody which specifically binds to a protein encoded by a nucleic acid comprising a nucleic acid sequence selected from the group consisting of the sequences outlined in Tables 1-40 wherein said antibody is a monoclonal antibody, a polyclonal antibody, a bi-specific antibody, a chimeric antibody, a humanized antibody, a single-chain antibody, a Fab or a Fab₂ fragment.~~

Claims 17-19 (Canceled)

20. **(New)** The isolated antibody of claim 15 wherein the antibody is conjugated to a therapeutic moiety.

21. **(New)** The isolated antibody of claim 15 wherein the antibody binds to the protein with a binding constant between 10^{-7} - 10^{-9} M⁻¹.

CHIR0035-100 (PP023796.0001)
SERIAL NO.: 10/052,482

PATENT
FILED: November 8, 2001

22. (New) A composition comprising the isolated antibody of claim 15 and a pharmaceutically acceptable carrier.